Login to Your Account



BioVex Raises £17M, Aims For Phase II OncoVEX Trial

By Nuala Moran


Tuesday, October 7, 2003
LONDON - BioVex Ltd. raised £17 million in third-round funding, giving it the means to start a U.S. Phase II trial of its lead cancer vaccine, OncoVEX, and move ImmunoVEX into Phase I work. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription